News:
Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion - AbbVie to Buy ImmunoGen for More Than $10 Billion
ImmunoGen
Bookmark
ShareKey facts
- city: Waltham
- state: MA
- country: United States
- sector: Health Care
- foundation year: 1981
- industry: Biotechnology
- CEO: Mark Joseph Enyedy
- CEO gender: Male
Classified as: organization
Summary
ImmunoGen is a company. It is located in Waltham, the United States and was founded in 1981. The company is part of the Health Care sector, specifically in the Biotechnology industry.
Business
ImmunoGen is one of the companies in the United States, companies in Biotechnology, companies in Health Care and 3,466,499 companies in our database.
- Assets: 525.8M $
- Debt: 0.00 $
- Employees: 106 people
- Free cash flow: -97827200 $
- Market cap: 1.1B $
- Revenues: 89.4M $
Stocks from ImmunoGen
Explore more on business
Talking Points:
- ImmunoGen | Target a Better Now | ADC TechnologyFocused Cancer Treatment
- Target a better now with ImmunoGen, Inc., a biotechnology company focused on the development of antibody-drug conjugate (ADC) technology to treat cancer.
- Interrupting the progress of cancer so cancer can't interrupt the lives of our patients. | Targeting a better life for people with cancer is why we get up in the morning. It's not enough to disrupt the progress of someone's cancer; we want to keep cancer from disrupting someone's life. That's why everything we do is about developing the ...
- ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
Learn more about talking points